PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12084393-3	2002	In this study, we have observed that AZT exposure also induced a concentration dependent suppressive effect (35-90%) on GM-CSF receptor type alpha (GM-CSFR alpha) gene expression.	Zidovudine	37-40	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	120-126	
12084393-8	2002	These data also suggest that a combination of GM-CSF and IL-3 may be a superior therapeutic intervention for AZT-induced neutropenia.	Zidovudine	109-112	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	46-52	
8788116-8	1995	These results indicate that the combination use of IL-3 and GM-CSF in vivo is only a partially effective growth factor/cytokine treatment to ameliorate the hematopoietic toxicity associated with the use of the anti-viral drug zidovudine.	Zidovudine	226-236	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	60-66	
7950902-0	1994	Prevention of hematopoietic myeloid and megakaryocyte toxicity associated with zidovudine in vivo in mice with recombinant GM-CSF.	Zidovudine	79-89	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	123-129	
7950902-5	1994	GM-CSF reduced zidovudine-induced myeloid toxicity (concentration < 2.5 mg/ml) which was associated with an increase in bone marrow and splenic CFU-GM.	Zidovudine	15-25	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-6	
7950902-7	1994	GM-CSF induced a reduction in circulating platelets following zidovudine treatment at weeks 2 and 4 with the 1.0 mg/ml and 2.5 mg/ml treatment groups respectively, compared to a persistent decrease in platelets in the presence of zidovudine alone.	Zidovudine	62-72	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-6	
7950902-7	1994	GM-CSF induced a reduction in circulating platelets following zidovudine treatment at weeks 2 and 4 with the 1.0 mg/ml and 2.5 mg/ml treatment groups respectively, compared to a persistent decrease in platelets in the presence of zidovudine alone.	Zidovudine	230-240	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-6	
8274295-1	1993	We studied the effect of interleukin-1 (IL-1 alpha) either alone or administered with GM-CSF on the induction of hematopoietic toxicity associated with zidovudine (AZT) in vivo, as determined by peripheral blood indices, and assays of hematopoietic progenitors, i.e., erythroid (BFU-E), myeloid (CFU-GM), and megakaryocyte (CFU-Meg) cultured from bone marrow and spleen.	Zidovudine	152-162	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	86-92	
8274295-3	1993	Daily administration of IL-1 alpha (recombinant murine, 5 u/animal) with or without GM-CSF (recombinant murine (10 micrograms/kg/bw) was associated with reduced AZT-toxicity as measured by increases in peripheral blood indices and progenitor stem cells, i.e., CFU-GM, CFU-Meg and BFU-E cultured from either bone marrow and spleen.	Zidovudine	161-164	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	84-90	
8274295-5	1993	These results demonstrate IL-1 with or without GM-CSF reverses AZT-hematopoietic toxicity when used in vivo.	Zidovudine	63-66	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	47-53	
1940611-6	1991	We report the results of further studies designed to investigate the ability of GM-CSF, erythropoietin, interleukin-1, and lithium to modulate AZT toxicity on murine hematopoietic granulocyte-macrophage (CFU-GM), megakaryocytic (CFU-Meg), and erythroid (BFU-E) progenitors cultured from bone marrow and spleen cells from mice infected with RLV.	Zidovudine	143-146	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	80-86